Reza Raeisossadati

Reza Raeisossadati

Auto-generated profile, based on publicly available information

Reza Raeisossadati

Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2015 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
VPVera Paschon
Vera Paschon
STSilvia Honda Takada
Silvia Honda Takada
JIJuliane Midori Ikebara
Juliane Midori Ikebara
ESErica Sousa
Erica Sousa
RRReza Raeisossadati
Reza Raeisossadati
AKAlexandre Hiroaki Kihara
Alexandre Hiroaki Kihara

1 January 2013 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
MFMohammad Mahdi Forghanifard
Mohammad Mahdi Forghanifard
MMMeysam Moghbeli
Meysam Moghbeli
RRReza Raeisossadati
Reza Raeisossadati
ATAlireza Tavassoli
Alireza Tavassoli
AMAfsaneh Javdani Mallak
Afsaneh Javdani Mallak
MAMohammad Reza Abbaszadegan
Mohammad Reza Abbaszadegan
Human cancer cells resemble stem cells in expression signatures leading them to share some features, most notably, self-renewal. A complex network of transcription factors and signaling molecules are required for continuance of this trait. SALL4 is a zinc finger transcriptional activator crucial for maintenance of self-renewal in stem cells; however, its expression level has not yet been elucidated in colorectal tumor cells. To determine this level and probable clinicopathological consequences, its expression was analyzed.

26 August 2014 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SKSima Ardalan Khales
Sima Ardalan Khales
MAMohammad Reza Abbaszadegan
Mohammad Reza Abbaszadegan
AAAbbas Abdollahi
Abbas Abdollahi
RRReza Raeisossadati
Reza Raeisossadati
MTMohsen Fallah Tousi
Mohsen Fallah Tousi
MFMohammad Mahdi Forghanifard
Mohammad Mahdi Forghanifard

1 August 2011 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
MFMohammad Mahdi Forghanifard
Mohammad Mahdi Forghanifard
MGMehran Gholamin
Mehran Gholamin
MFMoein Farshchian
Moein Farshchian
OMOmeed Moaven
Omeed Moaven
BMBahram Memar
Bahram Memar
MAMohammad Reza Abbaszadegan
Mohammad Reza Abbaszadegan
Cancer-testis antigens (CTAs) are often specifically expressed in cancer cells and under normal conditions are only considered to be expressed in the germ line cells and the placenta. CTAs are potential targets for cancer immunotherapy and therefore necessitates their expression profiling. The expression profile of LAGE1, MAGE-A4 and NY-ESO1, their possible correlations and interaction, and the clinicopathological associations of each marker were studied. RNA was extracted from fresh esophagectomy tissues of 41 esophageal squamous cell carcinoma (ESCC) patients prior to any other therapeutic intervention. The relative mRNA expression of LAGE1, MAGE-A4 and NY-ESO1 was assessed with the real-time reverse transcription-polymerase chain reaction (RT-PCR) 5‘ nuclease assay. The overexpression of LAGE1, MAGE-A4 and NY-ESO1 was found in 39, 90.2 and 41.4% of ESCC samples respectively. Of the patients, 97.5% showed an overexpression of at least one CTA. The relative expression of MAGE-A4 was directly associated with lymph node metastasis and the stage of the tumor (p < 0.05). A significant direct correlation was also detected between the MAGE-A4/LAGE1 and MAGE-A4/NY-ESO1 levels of gene expression. MAGE-A4 is identified as a specific biomarker of ESCC with a possible oncogenic role contributing to tumor progression. Interactions between MAGE-A4, LAGE1 and NY-ESO1 and their significant clinical consequences introduce these CTAs as appropriate targets for a polyvalent cancer vaccine.

18 October 2011 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MFMohammad Mahdi Forghanifard
Mohammad Mahdi Forghanifard
OMOmeed Moaven
Omeed Moaven
MFMoein Farshchian
Moein Farshchian
Mehdi MontazerMehdi Montazer
Mehdi Montazer
RRReza Raeisossadati
Reza Raeisossadati
MAMohammad Reza Abbaszadegan
Mohammad Reza Abbaszadegan

1 January 2020 in Theranostics
Verified
Journal Article
Open access
YTYacine Touahri
Yacine Touahri
RDRajiv Dixit
Rajiv Dixit
RKRikke Hahn Kofoed
Rikke Hahn Kofoed
KMKristina Miloska
Kristina Miloska
EPEunJee Park
EunJee Park
CSCarol Schuurmans
Carol Schuurmans
Müller glia are specialized retinal cells with stem cell properties in fish and frogs but not in mammals. Current efforts to develop gene therapies to activate mammalian Müller glia for retinal repair will require safe and effective delivery strategies for recombinant adeno-associated viruses (AAVs), vectors of choice for clinical translation. Intravitreal and subretinal injections are currently used for AAV gene delivery in the eye, but less invasive methods efficiently targeting Müller glia have yet to be developed.